Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: Ten-year follow-up data analyzed with marginal structural models and propensity score methods

Michael McCulloch, Michael Broffman, Mark Van Der Laan, Alan Hubbard, Lawrence Kushi, Alan Kramer, Jin Gao, John M. Colford

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.

Original languageEnglish (US)
Pages (from-to)260-279
Number of pages20
JournalIntegrative Cancer Therapies
Volume10
Issue number3
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Propensity Score
Herbal Medicine
Structural Models
Systems Analysis
Vitamins
Lung Neoplasms
Survival
Medicine
Therapeutics
Complementary Therapies
Drug Therapy
San Francisco
Non-Small Cell Lung Carcinoma
Observational Studies
Registries
Radiotherapy
Survival Rate
Retrospective Studies

Keywords

  • chemotherapy
  • Chinese herbal medicine
  • lung cancer
  • marginal structural models
  • propensity score
  • radiotherapy
  • survival
  • vitamins

ASJC Scopus subject areas

  • Complementary and alternative medicine
  • Oncology

Cite this

Lung cancer survival with herbal medicine and vitamins in a whole-systems approach : Ten-year follow-up data analyzed with marginal structural models and propensity score methods. / McCulloch, Michael; Broffman, Michael; Van Der Laan, Mark; Hubbard, Alan; Kushi, Lawrence; Kramer, Alan; Gao, Jin; Colford, John M.

In: Integrative Cancer Therapies, Vol. 10, No. 3, 09.2011, p. 260-279.

Research output: Contribution to journalArticle

McCulloch, Michael ; Broffman, Michael ; Van Der Laan, Mark ; Hubbard, Alan ; Kushi, Lawrence ; Kramer, Alan ; Gao, Jin ; Colford, John M. / Lung cancer survival with herbal medicine and vitamins in a whole-systems approach : Ten-year follow-up data analyzed with marginal structural models and propensity score methods. In: Integrative Cancer Therapies. 2011 ; Vol. 10, No. 3. pp. 260-279.
@article{259d313ff688458b9f321284b29f0c8f,
title = "Lung cancer survival with herbal medicine and vitamins in a whole-systems approach: Ten-year follow-up data analyzed with marginal structural models and propensity score methods",
abstract = "Complementary and alternative medicines are used by up to 48{\%} of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83{\%} and stage IV by 72{\%} compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46{\%}, stage IIIB by 62{\%}, and stage IV by 69{\%} compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82{\%} at 1 year, 68{\%} at 2 years, and 14{\%} at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.",
keywords = "chemotherapy, Chinese herbal medicine, lung cancer, marginal structural models, propensity score, radiotherapy, survival, vitamins",
author = "Michael McCulloch and Michael Broffman and {Van Der Laan}, Mark and Alan Hubbard and Lawrence Kushi and Alan Kramer and Jin Gao and Colford, {John M.}",
year = "2011",
month = "9",
doi = "10.1177/1534735411406439",
language = "English (US)",
volume = "10",
pages = "260--279",
journal = "Integrative Cancer Therapies",
issn = "1534-7354",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Lung cancer survival with herbal medicine and vitamins in a whole-systems approach

T2 - Ten-year follow-up data analyzed with marginal structural models and propensity score methods

AU - McCulloch, Michael

AU - Broffman, Michael

AU - Van Der Laan, Mark

AU - Hubbard, Alan

AU - Kushi, Lawrence

AU - Kramer, Alan

AU - Gao, Jin

AU - Colford, John M.

PY - 2011/9

Y1 - 2011/9

N2 - Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.

AB - Complementary and alternative medicines are used by up to 48% of lung cancer patients but have seen little formal assessment of survival efficacy. In this 10-year retrospective survival study, the authors investigated Pan-Asian medicine + vitamins (PAM+V) therapy in a consecutive case series of all non-small-cell lung cancer patients (n = 239) presenting at a San Francisco Bay Area Chinese medicine center (Pine Street Clinic). They compared short-term treatment lasting the duration of chemotherapy/radiotherapy with long-term therapy continuing beyond conventional therapy. They also compared PAM+V plus conventional therapy with conventional therapy alone, using concurrent controls from the Kaiser Permanente Northern California and California Cancer Registries. They adjusted for confounding with Kaplan-Meier, Cox regression, and newer methods-propensity score and marginal structural models (MSMs), which when analyzing data from observational studies or clinical practice records can provide results comparable with randomized trials. Long-term use of PAM+V beyond completion of chemotherapy reduced stage IIIB deaths by 83% and stage IV by 72% compared with short-term use only for the duration of chemotherapy. Long-term PAM+V combined with conventional therapy reduced stage IIIA deaths by 46%, stage IIIB by 62%, and stage IV by 69% compared with conventional therapy alone. Survival rates for stage IV patients treated with PAM+V were 82% at 1 year, 68% at 2 years, and 14% at 5 years. PAM+V combined with conventional therapy improved survival in stages IIIA, IIIB, and IV, compared with conventional therapy alone. Prospective trials using PAM+V with conventional therapy for lung cancer patients are justified.

KW - chemotherapy

KW - Chinese herbal medicine

KW - lung cancer

KW - marginal structural models

KW - propensity score

KW - radiotherapy

KW - survival

KW - vitamins

UR - http://www.scopus.com/inward/record.url?scp=84855363742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855363742&partnerID=8YFLogxK

U2 - 10.1177/1534735411406439

DO - 10.1177/1534735411406439

M3 - Article

C2 - 21824893

AN - SCOPUS:84855363742

VL - 10

SP - 260

EP - 279

JO - Integrative Cancer Therapies

JF - Integrative Cancer Therapies

SN - 1534-7354

IS - 3

ER -